Get started
Author

Sonia K. Morgan‐Linnell

Observed names: S. Morgan-Linnell, S.K. Morgan-Linnell, Sonia K Morgan-Linnell, Sonia K. Morgan-Linnell, Sonia Morgan-Linnell
ORCID: 0000-0002-7013-8908
Observed ORCID: 0000-0002-7013-8908
OpenAlex ID: A5065787591
Expression of Multidrug Efflux Pump Genes acrAB-tolC , mdfA , and norE in Escherichia coli Clinical Isolates as a Function of Fluoroquinolone and Multidrug Resistance
2010 · Michelle C. Swick, Sonia K. Morgan-Linnell, et al. · Antimicrobial Agents and Chemotherapy · 241
Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
2008 · Sonia K. Morgan-Linnell, Lauren Becnel Boyd, et al. · Antimicrobial Agents and Chemotherapy · 166
Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates
2008 · Lauren Becnel Boyd, Merry J. Maynard, et al. · Antimicrobial Agents and Chemotherapy · 85
Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coli
2007 · Sonia K. Morgan-Linnell, Lynn Zechiedrich · Antimicrobial Agents and Chemotherapy · 62
Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
2012 · Razelle Kurzrock, Sanjay Goel, et al. · Cancer · 51
Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
2013 · Gerald S. Falchook, Aung Naing, et al. · Oncotarget · 35
PDF
U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
2014 · Sonia K. Morgan-Linnell, David J. Stewart, et al. · Clinical Cancer Research · 14
The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma
2024 · Sebastian Podlipnik, Brian J. Martin, et al. · Cancers · 12
PDF
Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31‐gene expression profile test
2022 · Kelli Ahmed, Jennifer J. Siegel, et al. · Cancer Medicine · 11
Assessing Sensitivity to Antibacterial Topoisomerase II Inhibitors
2007 · Sonia K. Morgan‐Linnell, Hiroshi Hiasa, et al. · Current Protocols in Pharmacology · 8
The health economic impact of the 31-gene expression profile test for treatment and surveillance management plans in patients with cutaneous melanoma
2024 · D. Zakria, J. Burshtein, et al. · EJC Skin Cancer · 2
PDF
Abstract 3344: The 31-gene expression profile identifies patients at risk of developing early distant metastases and can guide risk-appropriate surveillance strategies
2025 · Merve Hasanov, Elshad Hasanov, et al. · Cancer Research · 1
62266 Real-world evidence demonstrates the 31-GEP stratifies risk of melanoma-specific mortality and is associated with improved survival: A SEER collaboration
2025 · Sonia K. Morgan-Linnell, Jason M. Rizzo, et al. · Journal of the American Academy of Dermatology
The 31-GEP Stratifies Risk of Death in Patients with Stage I-IIA Cutaneous Melanoma: A SEER Real-World Evidence Study
2025 · Harrison Nguyen, Christine N. Bailey, et al. · SKIN The Journal of Cutaneous Medicine
PDF
The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: An NCI-SEER analysis.
2025 · Merve Hasanov, Brian Martin, et al. · Journal of Clinical Oncology
PDF
CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality
2025 · Harrison Nguyen, Christine N. Bailey, et al. · Journal of the National Comprehensive Cancer Network
66 Prospective study shows 31-gene expression profile test stratifies recurrence-free survival and improves American Joint Committee on Cancer (AJCC) risk prediction in stage IB–IIA cutaneous melanoma
2024 · Etan Marks, Joseph Gadzia, et al. · Journal for ImmunoTherapy of Cancer
51667 31-GEP testing is associated with improved melanoma-specific survival relative to untested patients: an analysis of patients <65 years old
2024 · Brian Martin, Michael Tassavor, et al. · Journal of the American Academy of Dermatology
PDF
133 The 31-gene expression profile test stratifies recurrence-free and melanoma-specific survival in patients with stage IB-IIA and stage IIB cutaneous melanoma
2023 · Robert W Cook, Sonia K Morgan-Linnell, et al. · Journal for ImmunoTherapy of Cancer
PDF
43858 The 31-gene expression profile test for cutaneous melanoma identifies patients with stage IB- IIA disease who have recurrence risk similar to that of stage IIB-IIC disease
2023 · Abel Jarell, Abel Jarell, et al. · Journal of the American Academy of Dermatology
PDF
The i31-GEP for sentinel lymph node (SLN) biopsy outperforms the MSKCC nomogram in predicting the risk of having a positive SLN in patients with cutaneous melanoma
2023 · Danny Zakria, Sonia K. Morgan-Linnell, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Supplementary Figure 2 from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
2023 · Sonia K. Morgan-Linnell, David J. Stewart, et al.
PDF
Supplementary Figure 1 from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
2023 · Sonia K. Morgan-Linnell, David J. Stewart, et al.
PDF
Supplementary Figure Legends from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
2023 · Sonia K. Morgan-Linnell, David J. Stewart, et al.
PDF
Data from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
2023 · Sonia K. Morgan-Linnell, David J. Stewart, et al.
Works count: 29
Citation count: 688
H-index: 9
I10-index: 9
Year
Topic
Type